Pablo Legorreta is the founder, CEO and Chairman of Royalty Pharma, plc. Formed in 1996, Royalty Pharma has been the pioneer and market leader in royalty funding of life science innovation. The company’s collaborations span the entire research and development ecosystem, from academic institutions, research hospitals and not-for-profits to small- and mid-cap biotechnology companies and global pharmaceutical companies. To date, Royalty Pharma has deployed more than $20 billion of capital to advance innovation in the biopharmaceutical industry.

Legorreta is also co-founder of Pharmakon Advisors, a leading provider of debt capital to the life sciences industry; a co-founder of ProKidney, LLC, a biotech company developing pioneering therapies that have the potential to change the lives of people with chronic kidney disease; and founder and Chairman of Alianza Médica para la Salud, a non-profit dedicated to enhancing the quality of health care in Latin America by providing doctors and healthcare providers with continued education opportunities.

Legorreta spent 10 years at Lazard Freres, where he provided cross-border merger-and-acquisition and corporate finance advisory services to U.S. and European corporations. He serves on the Board of Governors of the New York Academy of Sciences as well as the Boards of Trustees of Rockefeller University, Brown University, the Hospital for Special Surgery, Pasteur Foundation (US), Open Medical Institute and Park Avenue Armory.

Legorreta received a degree in industrial engineering from Universidad Iberoamericana.

Healthcare, Health, Pharmaceutical, Leadership CEO, Chief Executive Officer (CEO), Mexican, Diversity & Inclusion, Milken Institute, Biotechnology, Innovation, Non-Profit,